(Q33670571)

28 July 2017

0 references

Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles (English)

1 reference

28 July 2017

1 reference

Henry ML

1

1 reference

28 July 2017

1 June 1999

1 reference

28 July 2017

Clinical Transplantation

1 reference

28 July 2017

13

1 reference

28 July 2017

3

1 reference

28 July 2017

209-220

1 reference

A Comparison of Tacrolimus (FK 506) and Cyclosporine for Immunosuppression in Liver Transplantation

28 July 2017

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

Randomised trialomania? The multicentre liver transplant trials of tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

FK506 and cyclosporin, molecular probes for studying intracellular signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

Tacrolimus, a new immunosuppressant--a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

Safety and tolerability of cyclosporine microemulsion versus cyclosporine: two-year data in primary renal allograft recipients: a report of the Neoral Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

FK 506 for liver, kidney, and pancreas transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

Tacrolimus (FK506) is superior to cyclosporine in liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

Neoral vs Sandimmun: interim results of a randomized trial of efficacy and safety in preventing acute rejection in new renal transplant recipients. The U. K. Neoral Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

Solitary pancreas allografts. The role of percutaneous biopsy and standardized histologic grading of rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

7 January 2021

Mode of action of tacrolimus (FK506): molecular and cellular mechanisms.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

7 January 2021

An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

7 January 2021

Intra- and interindividual variation in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients--importance of trough level as a practical indicator

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

7 January 2021

The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients. The Neoral Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

7 January 2021

Consistent absorption of cyclosporine from a microemulsion formulation assessed in stable renal transplant recipients over a one-year study period

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

7 January 2021

Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

7 January 2021

Three-year follow-up of the European Multicenter Tacrolimus (FK506) Liver Study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

7 January 2021

Reduced acute rejection after liver transplantation with Neoral-based triple immunosuppression

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

7 January 2021

A microemulsion of cyclosporine without intravenous cyclosporine in liver transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

7 January 2021

The safety and tolerability of cyclosporine emulsion versus cyclosporine in a randomized, double-blind comparison in primary renal allograft recipients. The Neoral Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

7 January 2021

Neoral compared to Sandimmune is associated with a decrease in histologic severity of rejection in patients undergoing primary liver transplantation.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

7 January 2021

Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

7 January 2021

Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

7 January 2021

General guidelines for the use of tacrolimus in adult liver transplant patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

7 January 2021

Metabolic effects of cyclosporin A and FK 506 in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

7 January 2021

Commentary on a comparison of tacrolimus and cyclosporine for immunosuppression after cadaveric renal transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

7 January 2021

The effects of pravastatin on hyperlipidemia in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

7 January 2021

Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

7 January 2021

A comparison of renal function in cyclosporine- and FK-506-treated patients after primary orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

7 January 2021

Conversion from cyclosporine to FK506 for salvage of immunocompromised pediatric liver allografts. Efficacy, toxicity, and dose regimen in 23 children

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

7 January 2021

Variable effects of steroid withdrawal on blood pressure reduction in cyclosporine-treated renal transplant recipients.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

7 January 2021

Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

7 January 2021

Steroid withdrawal from long-term immunosuppression in liver allograft recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

7 January 2021

Steroid withdrawal 3 months after liver transplantation--does FK 506 confer any advantage over cyclosporin?

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130301.X

7 January 2021

10.1034/J.1399-0012.1999.130301.X

Identifiers

DOI

1 reference

28 July 2017

1 reference

PubMed ID

10383101